OncoMatch/Clinical Trials/NCT06569459
Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer
Is NCT06569459 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trilaciclib for esophageal cancer.
Treatment: Trilaciclib — This study is a double-arm, randomized, controlled, single-center, phase II clinical trial aimed at evaluating the efficacy and safety of chemoradiotherapy plus immunotherapy with or without Trilaciclib in the treatment of locally advanced esophageal squamous cell carcinoma that is not resectable.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Have not received any systemic anti-tumor therapy (including but not limited to systemic chemotherapy, radiotherapy, molecular targeted drug therapy, immunotherapy, biological therapy, local therapy, and other investigational therapeutic drugs)
Cannot have received: anti-PD-1 therapy
Have received or are receiving any of the following：Anti-PD-1 or anti-PD-L1 antibody therapy
Cannot have received: anti-PD-L1 therapy
Have received or are receiving any of the following：Anti-PD-1 or anti-PD-L1 antibody therapy
Cannot have received: chemotherapy
Have received or are receiving any of the following：...chemotherapy...
Cannot have received: radiotherapy
Have received or are receiving any of the following：...radiotherapy...
Cannot have received: targeted therapy
Have received or are receiving any of the following：...targeted therapy...
Cannot have received: investigational therapy
received any study drug within 4 weeks before the first dose of the study drug
Cannot have received: antitumor vaccine
Have received an antitumor vaccine or a live vaccine within 4 weeks before the first dose of study drug
Cannot have received: live vaccine
Have received an antitumor vaccine or a live vaccine within 4 weeks before the first dose of study drug
Cannot have received: hematopoietic stem cell or bone marrow transplantation
Prior hematopoietic stem cell or bone marrow transplantation
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1.5×10^9/L；Platelet count ≥100×10^9/L；Hemoglobin ≥100 g/L in women or 110g/L in men；Serum albumin ≥2.8g/dL
Kidney function
serum creatinine 1.5 x ULN or creatinine clearance or greater or less 60 ml/min (according to Cockcroft - Gault formula)
Liver function
Total bilirubin ≤1.5 × ULN and ALT, AST, and/or AKP≤2.5 × ULN
Vital organ function meets the following requirements (no blood components and cell growth factors are allowed for 2 weeks before the start of screening examination) ：Absolute neutrophil count (ANC) ≥1.5×10^9/L；Platelet count ≥100×10^9/L；Hemoglobin ≥100 g/L in women or 110g/L in men；Serum albumin ≥2.8g/dL；Total bilirubin ≤1.5 × ULN and ALT, AST, and/or AKP≤2.5 × ULN, serum creatinine 1.5 x ULN or creatinine clearance or greater or less 60 ml/min (according to Cockcroft - Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify